Terray Therapeutics, founded in 2018 in Pasadena, California, pairs very high-throughput chemistry experiments with AI models to discover small-molecule drugs. It raised a $120 million Series B in October 2024.
At a glance
| Price from | Custom |
| Best for | Drugmakers seeking small-molecule discovery partners |
From Terray Therapeutics's own website.
What stands out
- Generates its own large chemistry datasets
- Clear small-molecule focus
Worth knowing
- Pipeline still preclinical
- Less public detail than larger peers
How it ranks
Terray Therapeutics is ranked 9th of 10 in Best AI Drug Discovery Startups (Lister Score 86.7).
#9 in Best AI Drug Discovery Startups · Lister Score 86.7
Terray's TerrayEMMI platform combines its own experimental data with machine learning..
| Rank | Best AI Drug Discovery Startups | Score |
|---|---|---|
| 1 | Isomorphic Labs | 97.1 |
| 2 | Xaira Therapeutics | 95.8 |
| 3 | Chai Discovery | 94.6 |
| 4 | Enveda | 93.3 |
| 5 | insitro | 92.0 |
| 6 | Formation Bio | 90.7 |
| 7 | Genesis Molecular AI | 89.4 |
| 8 | BigHat Biosciences | 88.1 |
| 9 | Terray Therapeutics | 86.7 |
| 10 | Cradle | 85.3 |
Frequently asked questions
How does Terray Therapeutics rank on Lister?
Terray Therapeutics is ranked 9th of 10 in Best AI Drug Discovery Startups (Lister Score 86.7).
Appears in
Add this badge to your site
If you work at Terray Therapeutics, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.